Clinical Trial: Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895499) titled 'Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.' on March 07.

Brief Summary: The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.

Study Start Date: March 20

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa

Intervention: DRUG: HB0043

Low dose

DRUG: HB0043

Medium dose

DRUG: HB0043

High dose

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....